SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-16-612779
Filing Date
2016-06-03
Accepted
2016-06-03 17:08:03
Documents
55
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d160065d10q.htm 10-Q 537258
2 EX-31.1 d160065dex311.htm EX-31.1 5718
3 EX-31.2 d160065dex312.htm EX-31.2 5719
4 EX-32.1 d160065dex321.htm EX-32.1 3542
11 GRAPHIC g160065txpg017.jpg GRAPHIC 95498
  Complete submission text file 0001193125-16-612779.txt   2647659

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT ntla-20160331.xml EX-101.INS 317957
6 XBRL TAXONOMY EXTENSION SCHEMA ntla-20160331.xsd EX-101.SCH 34013
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ntla-20160331_cal.xml EX-101.CAL 43036
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ntla-20160331_def.xml EX-101.DEF 108765
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20160331_lab.xml EX-101.LAB 273549
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20160331_pre.xml EX-101.PRE 198106
Mailing Address 130 BROOKLINE STREET SUITE 201 CAMBRIDGE MA 02139
Business Address 130 BROOKLINE STREET SUITE 201 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 161696584
SIC: 2835 In Vitro & In Vivo Diagnostic Substances